Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants

Neurologic Clinics

Volumn 33, Issue 4, 2015, Pages 855-876

  Saberi, Shahram ^a   Stauffer, Jennifer E ^a   Schulte, Derek J ^a   Ravits, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyotrophic lateral sclerosis; C9orf72; Motor neuron degeneration; Neuropathology; TDP 43

Indexed keywords

ALPHA SYNUCLEIN; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOOXYGENASE 2; FUSED IN SARCOMA PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; PROTEIN BAX; PROTEIN BCL 2; SURVIVAL MOTOR NEURON PROTEIN 1; TAR DNA BINDING PROTEIN; TAU PROTEIN; UBIQUITIN; C9ORF72 PROTEIN, HUMAN; DNA BINDING PROTEIN; PROTEIN; TDP-43 PROTEIN, HUMAN;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ASTROCYTOSIS; BRAIN ATROPHY; C9ORF72 GENE; CHROMATOLYSIS; DISEASE CLASSIFICATION; DNA FRAGMENTATION; FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS; FRONTOTEMPORAL DEMENTIA; FUS GENE; GENE; GENE MUTATION; GENETIC ASSOCIATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MICROGLIA; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROAXONAL DYSTROPHY; NEUROPATHOLOGY; NONHUMAN; OVERLAP FRONTOTEMPORAL DEMENTIA; PHENOTYPE; PRIMARY LATERAL SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MUSCULAR ATROPHY; REVIEW; SMN1 GENE; SOD1 GENE; SOMATODENDRITIC ATTRITION; SPINAL CORD VENTRAL HORN; SPINAL MUSCULAR ATROPHY; TDP 43 GENE; TDP 43 PROTEINOPATHY; GENETIC VARIATION; GENETICS; PATHOLOGY; PATHOPHYSIOLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; DNA-BINDING PROTEINS; GENETIC VARIATION; HUMANS; PROTEINS;

EID: 84945953187     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2015.07.012     Document Type: Review

References (151)

1. Tyler H.R., Shefner J. Amyotrophic lateral sclerosis. Handb Clin Neurol 1991, 15:169-215.
2. Aran F. Recherches sur une maladie non encore décrite du système musculaire (atrophie musculaire progressive). Arch Gen Med 1850, 24:172.
3. Cruveilhier J. Sur la paralysie musculaire progressive atrophique. Arch Gen Med 1853, 91:561-603.
4. Duchenne de Boulogne G. Recherches électro-physiologiques et thérapeutiques. Comp Rend Seances Acad Sci 1851, 32:506.
5. Charcot J.M., Joffroy A. Deux cas d'atrophie musculaire progressive: avec lésions de la substance grise et des faisceaux antérolatéraux de la moelle épinière 1869, Masson, Paris.
6. Charcot J. De la sclérose latérale amyotrophique. Prog Med 1874, 2:341-453.
7. Brodmann K. Vergleichende Lokalisationslehre der Grosshirnrinde in ihren Prinzipien dargestellt auf Grund des Zellenbaues 1909, Barth, Leipzig (Germany).
8. Bunina T. On intracellular inclusions in familial amyotrophic lateral sclerosis. Zh Nevropatol Psikhiatr Im S S Korsakova 1961, 62:1293-1299. [in Russian].
9. Leigh P., Anderton B., Dodson A., et al. Ubiquitin deposits in anterior horn cells in motor neurone disease. Neurosci Lett 1988, 93:197-203.
10. Lowe J., Lennox G., Jefferson D., et al. A filamentous inclusion body within anterior horn neurones in motor neurone disease defined by immunocytochemical localisation of ubiquitin. Neurosci Lett 1988, 94:203-210.
11. Arai T., Hasegawa M., Akiyama H., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006, 351:602-611.
12. Neumann M., Sampathu D.M., Kwong L.K., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
13. Hudson A.J. Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review. Brain 1981, 104:217-247.
14. Kiernan J.A., Hudson A.J. Frontal lobe atrophy in motor neuron diseases. Brain 1994, 117(Pt 4):747-757.
15. Rosen D.R., Siddique T., Patterson D., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362(6415):59-62.
16. Sreedharan J., Blair I.P., Tripathi V.B., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672.
17. Vance C., Rogelj B., Hortobagyi T., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009, 323:1208-1211.
18. Kwiatkowski T.J., Bosco D.A., Leclerc A.L., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323:1205-1208.
19. Renton A.E., Majounie E., Waite A., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72:257-268.
20. DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72:245-256.
21. Ellison D., Love S., Chimelli L.M.C., et al. Neuropathology: a reference text of CNS pathology 2012, Elsevier Health Sciences, London.
22. Chang J., Lomen-Hoerth C., Murphy J., et al. A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD. Neurology 2005, 65:75-80.
23. Abrahams S., Goldstein L., Suckling J., et al. Frontotemporal white matter changes in amyotrophic lateral sclerosis. J Neurol 2005, 252:321-331.
24. Murphy J.M., Henry R.G., Langmore S., et al. Continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol 2007, 64:530-534.
25. Kassubek J., Unrath A., Huppertz H.J., et al. Global brain atrophy and corticospinal tract alterations in ALS, as investigated by voxel-based morphometry of 3-D MRI. Amyotroph Lateral Scler Other Motor Neuron Disord 2005, 6:213-220.
26. Roccatagliata L., Bonzano L., Mancardi G., et al. Detection of motor cortex thinning and corticospinal tract involvement by quantitative MRI in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009, 10:47-52.
27. Hammer R.P., Tomiyasu U., Scheibel A.B. Degeneration of the human Betz cell due to amyotrophic lateral sclerosis. Exp Neurol 1979, 63:336-346.
28. Nihei K., McKee A.C., Kowall N.W. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathol 1993, 86:55-64.
29. Dickson D., Weller R.O. Neurodegeneration: the molecular pathology of dementia and movement disorders 2011, John Wiley & Sons, Singapore.
30. Stephens B., Guiloff R.J., Navarrete R., et al. Widespread loss of neuronal populations in the spinal ventral horn in sporadic motor neuron disease. A morphometric study. J Neurol Sci 2006, 244:41-58.
31. Piao Y.S., Wakabayashi K., Kakita A., et al. Neuropathology with clinical correlations of sporadic amyotrophic lateral sclerosis: 102 autopsy cases examined between 1962 and 2000. Brain Pathol 2003, 13:10-22.
32. Tomonaga M., Saito M., Yoshimura M., et al. Ultrastructure of the Bunina bodies in anterior horn cells of amyotrophic lateral sclerosis. Acta Neuropathol 1978, 42:81-86.
33. Kuroda S., Ishizu H., Kawai K., et al. Bunina bodies in dendrites of patients with amyotrophic lateral sclerosis. Acta Med Okayama 1990, 44:41-45.
34. Okamoto K., Mizuno Y., Fujita Y. Bunina bodies in amyotrophic lateral sclerosis. Neuropathology 2008, 28:109-115.
35. Sasaki S., Maruyama S. Immunocytochemical and ultrastructural studies of the motor cortex in amyotrophic lateral sclerosis. Acta Neuropathol 1994, 87:578-585.
36. Okamoto K., Hirai S., Ishiguro K., et al. Light and electron microscopic and immunohistochemical observations of the Onuf's nucleus of amyotrophic lateral sclerosis. Acta Neuropathol 1991, 81:610-614.
37. Okamoto K., Hirai S., Amari M., et al. Bunina bodies in amyotrophic lateral sclerosis immunostained with rabbit anti-cystatin C serum. Neurosci Lett 1993, 162:125-128.
38. Mizuno Y., Fujita Y., Takatama M., et al. Peripherin partially localizes in Bunina bodies in amyotrophic lateral sclerosis. J Neurol Sci 2011, 302:14-18.
39. Mizuno Y., Amari M., Takatama M., et al. Transferrin localizes in Bunina bodies in amyotrophic lateral sclerosis. Acta Neuropathol 2006, 112:597-603.
40. Sasaki S., Komori T., Iwata M. Neuronal inclusions in sporadic motor neuron disease are negative for alpha-synuclein. Neurosci Lett 2006, 397:15-19.
41. Mizuno Y., Amari M., Takatama M., et al. Immunoreactivities of p62, an ubiquitin-binding protein, in the spinal anterior horn cells of patients with amyotrophic lateral sclerosis. J Neurol Sci 2006, 249:13-18.
42. Murayama S., Mori H., Ihara Y., et al. Immunocytochemical and ultrastructural studies of lower motor neurons in amyotrophic lateral sclerosis. Ann Neurol 1990, 27:137-148.
43. Boillée S., Vande Velde C., Cleveland Don W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:39-59.
44. McGeer P.L., McGeer E.G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2002, 26:459-470.
45. Boillée S., Yamanaka K., Lobsiger C.S., et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006, 312:1389-1392.
46. Yamanaka K., Chun S.J., Boillee S., et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008, 11:251-253.
47. Schiffer D., Fiano V. Astrogliosis in ALS: possible interpretations according to pathogenetic hypotheses. Amyotroph Lateral Scler 2004, 5:22-25.
48. Barbeito L.H., Pehar M., Cassina P., et al. A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Brain Res Rev 2004, 47:263-274.
49. Lasiene J., Yamanaka K. Glial cells in amyotrophic lateral sclerosis. Neurol Res Int 2011, 2011:718987.
50. Henkel J., Beers D., Zhao W., et al. Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol 2009, 4:389-398.
51. Leigh P., Whitwell H., Garofalo O., et al. Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis morphology, distribution, and specificity. Brain 1991, 114:775-788.
52. Bergmann M., Kuchelmeister K., Schmid K., et al. Different variants of frontotemporal dementia: a neuropathological and immunohistochemical study. Acta Neuropathol 1996, 92:170-179.
53. Ikeda K., Akiyama H., Arai T., et al. Morphometrical reappraisal of motor neuron system of Pick's disease and amyotrophic lateral sclerosis with dementia. Acta Neuropathol 2002, 104:21-28.
54. Jackson M., Lennox G., Lowe J. Motor neurone disease-inclusion dementia. Neurodegeneration 1996, 5:339-350.
55. Okamoto K., Murakami N., Kusaka H., et al. Ubiquitin-positive intraneuronal inclusions in the extramotor cortices of presenile dementia patients with motor neuron disease. J Neurol 1992, 239:426-430.
56. Okamoto K., Hirai S., Yamazaki T., et al. New ubiquitin-positive intraneuronal inclusions in the extra-motor cortices in patients with amyotrophic lateral sclerosis. Neurosci Lett 1991, 129:233-236.
57. Wightman G., Anderson V., Martin J., et al. Hippocampal and neocortical ubiquitin-immunoreactive inclusions in amyotrophic lateral sclerosis with dementia. Neurosci Lett 1992, 139:269-274.
58. Kawashima T., Kikuchi H., Takita M., et al. Skeinlike inclusions in the neostriatum from a case of amyotrophic lateral sclerosis with dementia. Acta Neuropathol 1998, 96:541-545.
59. Arai T., Nonaka T., Hasegawa M., et al. Neuronal and glial inclusions in frontotemporal dementia with or without motor neuron disease are immunopositive for p62. Neurosci Lett 2003, 342:41-44.
60. Geser F., Lee V.M., Trojanowski J.Q. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. Neuropathology 2010, 30:103-112.
61. Ayala Y.M., De Conti L., Avendaño-Vázquez S.E., et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J 2011, 30:277-288.
62. Volkening K., Leystra-Lantz C., Yang W., et al. Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). Brain Res 2009, 1305:168-182.
63. Buratti E., De Conti L., Stuani C., et al. Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J 2010, 277:2268-2281.
64. Kawahara Y., Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc Natl Acad Sci U S A 2012, 109:3347-3352.
65. Godena V.K., Romano G., Romano M., et al. TDP-43 regulates Drosophila neuromuscular junctions growth by modulating Futsch/MAP1B levels and synaptic microtubules organization. PLoS One 2011, 6:e17808.
66. Wang I., Wu L.S., Chang H.Y., et al. TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem 2008, 105:797-806.
67. Buratti E., Baralle F.E. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR Exon 9. J Biol Chem 2001, 276:36337-36343.
68. Giordana M.T., Piccinini M., Grifoni S., et al. TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol 2010, 20:351-360.
69. Thorpe J.R., Tang H., Atherton J., et al. Fine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy. J Neural Transm 2008, 115:1661-1671.
70. Geser F., O'Dwyer L., Hardiman O., et al. On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. Prog Neurobiol 2011, 95:649-662.
71. Mackenzie I.R., Neumann M., Baborie A., et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011, 122:111-113.
72. Davidson Y., Kelley T., Mackenzie I.R., et al. Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol 2007, 113:521-533.
73. Hasegawa M., Arai T., Nonaka T., et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 2008, 64:60-70.
74. Braak H., Ludolph A., Thal D.R., et al. Amyotrophic lateral sclerosis: dash-like accumulation of phosphorylated TDP-43 in somatodendritic and axonal compartments of somatomotor neurons of the lower brainstem and spinal cord. Acta Neuropathol 2010, 120:67-74.
75. Mori F., Tanji K., Zhang H.-X., et al. Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol 2008, 116:193-203.
76. Alves-Rodrigues A., Gregori L., Figueiredo-Pereira M.E. Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci 1998, 21:516-520.
77. Amador-Ortiz C., Lin W.L., Ahmed Z., et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 2007, 61:435-445.
78. Higashi S., Iseki E., Yamamoto R., et al. Concurrence of TDP-43, tau and α-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res 2007, 1184:284-294.
79. Uryu K., Nakashima-Yasuda H., Forman M.S., et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 2008, 67:555.
80. Nakashima-Yasuda H., Uryu K., Robinson J., et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 2007, 114:221-229.
81. Yokota O., Davidson Y., Arai T., et al. Effect of topographical distribution of α-synuclein pathology on TDP-43 accumulation in Lewy body disease. Acta Neuropathol 2010, 120:789-801.
82. Hasegawa M., Arai T., Akiyama H., et al. TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 2007, 130:1386-1394.
83. McKee A.C., Gavett B.E., Stern R.A., et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010, 69:918-929.
84. Geser F., Robinson J.L., Malunda J.A., et al. Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol 2010, 67:1238-1250.
85. Sathasivam S., Ince P., Shaw P. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol 2001, 27:257-274.
86. Martin L.J. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999, 58:459-471.
87. Brettschneider J., Del Tredici K., Irwin D.J., et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol 2014, 127:423-439.
88. Ravits J., Laurie P., Fan Y., et al. Implications of ALS focality rostral-caudal distribution of lower motor neuron loss postmortem. Neurology 2007, 68:1576-1582.
89. Re D.B., Le Verche V., Yu C., et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron 2014, 81:1001-1008.
90. Braak H., Brettschneider J., Ludolph A.C., et al. Amyotrophic lateral sclerosis-a model of corticofugal axonal spread. Nat Rev Neurol 2013, 9:708-714.
91. Brettschneider J., Del Tredici K., Toledo J.B., et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013, 74:20-38.
92. Renton A.E., Chiò A., Traynor B.J. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014, 17:17-23.
93. Boylan K. Familial Amyotrophic Lateral Sclerosis. Neurol Clin 2015, in press.
94. Ince P.G., Highley J.R., Kirby J., et al. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathol 2011, 122:657-671.
95. Ince P.G., Tomkins J., Slade J.Y., et al. Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase: molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases of ALS. J Neuropathol Exp Neurol 1998, 57:895-904.
96. Mizusawa H., Matsumoto S., Yen S.H., et al. Focal accumulation of phosphorylated neurofilaments within anterior horn cell in familial amyotrophic lateral sclerosis. Acta Neuropathol 1989, 79:37-43.
97. Okamoto Y., Shirakashi Y., Ihara M., et al. Colocalization of 14-3-3 proteins with SOD1 in Lewy body-like hyaline inclusions in familial amyotrophic lateral sclerosis cases and the animal model. PLoS One 2011, 6:e20427.
98. Nakamura S., Wate R., Kaneko S., et al. An autopsy case of sporadic amyotrophic lateral sclerosis associated with the I113T SOD1 mutation. Neuropathology 2014, 34:58-63.
99. Mackenzie I.R.A., Bigio E.H., Ince P.G., et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007, 61:427-434.
100. Bosco D.A., Morfini G., Karabacak N.M., et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 2010, 13:1396-1403.
101. Forsberg K., Jonsson P.A., Andersen P.M., et al. Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS One 2010, 5:e11552.
102. Forsberg K., Andersen P.M., Marklund S.L., et al. Glial nuclear aggregates of superoxide dismutase-1 are regularly present in patients with amyotrophic lateral sclerosis. Acta Neuropathol 2011, 121:623-634.
103. Liu H.N., Sanelli T., Horne P., et al. Lack of evidence of monomer/misfolded superoxide dismutase-1 in sporadic amyotrophic lateral sclerosis. Ann Neurol 2009, 66:75-80.
104. Kerman A., Liu H.-N., Croul S., et al. Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol 2010, 119:335-344.
105. Brotherton T.E., Li Y., Cooper D., et al. Localization of a toxic form of superoxide dismutase 1 protein to pathologically affected tissues in familial ALS. Proc Natl Acad Sci U S A 2012, 109:5505-5510.
106. Yokoseki A., Shiga A., Tan C.F., et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol 2008, 63:538-542.
107. Pesiridis G.S., Lee V.M., Trojanowski J.Q. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet 2009, 18:R156-R162.
108. Van Deerlin V.M., Leverenz J.B., Bekris L.M., et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol 2008, 7:409-416.
109. Verbeeck C., Deng Q., Dejesus-Hernandez M., et al. Expression of fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis. Mol Neurodegener 2012, 7:53.
110. Takanashi K., Yamaguchi A. Aggregation of ALS-linked FUS mutant sequesters RNA binding proteins and impairs RNA granules formation. Biochem Biophys Res Commun 2014, 452:600-607.
111. Vance C., Scotter E.L., Nishimura A.L., et al. ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Hum Mol Genet 2013, 22:2676-2688.
112. Deng H.X., Zhai H., Bigio E.H., et al. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann Neurol 2010, 67:739-748.
113. Mackenzie I.R., Ansorge O., Strong M., et al. Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: 2 distinct patterns correlating with disease severity and mutation. Acta Neuropathol 2011, 122:87-98.
114. Mackenzie I.R., Neumann M., Bigio E.H., et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010, 119:1-4.
115. Snowden J.S., Hu Q., Rollinson S., et al. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. Acta Neuropathol 2011, 122:99-110.
116. Pikkarainen M., Hartikainen P., Alafuzoff I. Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry. J Neuropathol Exp Neurol 2008, 67:280-298.
117. King A., Al-Sarraj S., Shaw C. Frontotemporal lobar degeneration with ubiquitinated tau-negative inclusions and additional α-synuclein pathology but also unusual cerebellar ubiquitinated p62-positive, TDP-43-negative inclusions. Neuropathology 2009, 29:466-471.
118. Bullock T.L., Clarkson W.D., Kent H.M., et al. The 1.6 angstroms resolution crystal structure of nuclear transport factor 2 (NTF2). J Mol Biol 1996, 260:422-431.
119. Zu T., Liu Y., Bañez-Coronel M., et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A 2013, 110:E4968-E4977.
120. Mori K., Weng S.-M., Arzberger T., et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013, 339:1335-1338.
121. Al-Sarraj S., King A., Troakes C., et al. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol 2011, 122:691-702.
122. Boxer A.L., Mackenzie I.R., Boeve B.F., et al. Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry 2011, 82:196-203.
123. Mackenzie I.R., Frick P., Neumann M. The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol 2014, 127:347-357.
124. Wojciechowska M., Krzyzosiak W.J. Cellular toxicity of expanded RNA repeats: focus on RNA foci. Hum Mol Genet 2011, 20:3811-3821.
125. Lagier-Tourenne C., Baughn M., Rigo F., et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A 2013, 110:E4530-E4539.
126. Mizielinska S., Lashley T., Norona F.E., et al. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol 2013, 126:845-857.
127. Gendron T.F., Bieniek K.F., Zhang Y.J., et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol 2013, 126:829-844.
128. Mori K., Arzberger T., Grasser F.A., et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol 2013, 126:881-893.
129. Cooper-Knock J., Higginbottom A., Stopford M.J., et al. Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy. Acta Neuropathol 2015, 130:1-13.
130. Ravits J. Focality, stochasticity and neuroanatomic propagation in ALS pathogenesis. Exp Neurol 2014, 262(Pt B):121-126.
131. Kosaka T., Fu Y.J., Shiga A., et al. Primary lateral sclerosis: upper-motor-predominant amyotrophic lateral sclerosis with frontotemporal lobar degeneration-immunohistochemical and biochemical analyses of TDP-43. Neuropathology 2012, 32:373-384.
132. Pringle C.E., Hudson A.J., Munoz D.G., et al. Primary lateral sclerosis: clinical features, neuropathology and diagnostic criteria. Brain 1992, 115:495-520.
133. Statland J.M., Barohn R.J., Dimachkie M.M., et al. Primary Lateral Sclerosis. Neurol Clin 2015, in press.
134. Kolind S., Sharma R., Knight S., et al. Myelin imaging in amyotrophic and primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14:562-573.
135. Dickson D.W., Josephs K.A., Amador-Ortiz C. TDP-43 in differential diagnosis of motor neuron disorders. Acta Neuropathol 2007, 114:71-79.
136. Swank R.L., Putnam T.J. Amyotrophic lateral sclerosis and related conditions: a clinical analysis. Arch Neurol Psychiatry 1943, 49:151-177.
137. Liewluck T., Saperstein D.S. Progressive Muscular Atrophy. Neurol Clin 2015, in press.
138. van Blitterswijk M., Vlam L., van Es M.A., et al. Genetic overlap between apparently sporadic motor neuron diseases. PLoS One 2012, 7:e48983.
139. Ince P., Evans J., Knopp M., et al. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology 2003, 60:1252-1258.
140. Geser F., Stein B., Partain M., et al. Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy. Acta Neuropathol 2011, 121:509-517.
141. Riku Y., Atsuta N., Yoshida M., et al. Differential motor neuron involvement in progressive muscular atrophy: a comparative study with amyotrophic lateral sclerosis. BMJ Open 2014, 4:e005213.
142. Lomen-Hoerth C., Anderson T., Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002, 59:1077-1079.
143. Lomen-Hoerth C., Murphy J., Langmore S., et al. Are amyotrophic lateral sclerosis patients cognitively normal?. Neurology 2003, 60:1094-1097.
144. Lunn M.R., Wang C.H. Spinal muscular atrophy. Lancet 2008, 371:2120-2133.
145. Alías L., Bernal S., Fuentes-Prior P., et al. Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of 4 novel mutations in the SMN1 gene. Hum Genet 2009, 125:29-39.
146. Zhang Z., Pinto A.M., Wan L., et al. Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal muscular atrophy. Proc Natl Acad Sci U S A 2013, 110:19348-19353.
147. Araki S., Hayashi M., Tamagawa K., et al. Neuropathological analysis in spinal muscular atrophy type II. Acta Neuropathol 2003, 106:441-448.
148. Turner B.J., Bäumer D., Parkinson N.J., et al. TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy. Neurosci 2008, 9:104.
149. Behan W.M., Maia M. Strümpell's familial spastic paraplegia: genetics and neuropathology. J Neurol Neurosurg Psychiatry 1974, 37:8-20.
150. Harding A. Hereditary spastic paraplegias. Semin Neurol 1993, 13:333.
151. Martinez-Lage M., Molina-Porcel L., Falcone D., et al. TDP-43 pathology in a case of hereditary spastic paraplegia with a NIPA1/SPG6 mutation. Acta Neuropathol 2012, 124(2):285-291.